<DOC>
	<DOCNO>NCT00510003</DOCNO>
	<brief_summary>The purpose study assess efficacy safety pimecrolimus cream 1 % relation improvement pruritus pediatric patient ( 2- 11- year-old ) mild moderate atopic dermatitis .</brief_summary>
	<brief_title>Assessment Pruritus Improvement With Pimecrolimus Treatment Areas Affected Mild-to-moderate AD , Patients 2- 11- Year-old</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Male female . Age : 2 12 year . Outpatients diagnosis atopic dermatitis Atopic dermatitis affect â‰¥ 5 % Total Body Surface Area Baseline Investigator 's Global Assessment score 2 ( mild ) 3 ( moderate ) . Baseline visit pruritus ( itch ) severity assessment score 2 ( moderate ) 3 ( severe ) . Patients patient 's legal guardian inform study procedure sign informed consent form approve study prior start study related procedure , include washout ( case would necessary ) . Patients breastfed woman receive systemic prohibit medication . Children known hypersensitivity study medication . Children receive phototherapy systemic therapy ( immunosuppressant , cytostatics ) know affect atopic dermatitis within previous month topical therapy ( tar , topical corticosteroid ) , systemic corticosteroid , systemic antibiotic leukotriene antagonist within previous week . Children receive investigational drug within 8 week prior first application study medication . Children concurrent skin disease active bacterial , viral fungal infection . Immunocompromised child ( e.g. , lymphoma , AIDS , WiskottAldrich Syndrome ) child history malignant disease . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atopic dermatitis , child , pimecrolimus , eczema</keyword>
</DOC>